Presented by Andrew D. Zelenetz, MD, PhD, Professor of Medicine, Weill Medical College of Cornell University, and Vice Chair, Medical Informatics, Department of Medicine, and Attending Physician in the Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, New York.
J Natl Compr Canc Netw. 2014 May;12(5 Suppl):797-800. doi: 10.6004/jnccn.2014.0193.
During his presentation at the NCCN 19th Annual Conference, Dr. Andrew D. Zelenetz reviewed the updates to the 2014 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Hodgkin's Lymphomas. Dr. Zelenetz first discussed the updates for diffuse large B-cell lymphoma (DLBCL), focusing primarily on the emergence of MYC-positive DLBCL; the limited role of imaging in early-stage disease; new treatment options; the challenge of tumor heterogeneity; and the impact of cell of origin in the selection of future therapies. Then, on behalf of Dr. Steven Horwitz, Dr. Zelenetz presented the new guidelines for primary cutaneous CD30+ T-cell lymphoproliferative disorders and T-cell large granular lymphocytic leukemia.
在 NCCN 第 19 届年会上的演讲中，Andrew D. Zelenetz 博士回顾了 2014 年 NCCN 肿瘤学临床实践指南（NCCN 指南）中对非霍奇金淋巴瘤的更新。Zelenetz 博士首先讨论了弥漫性大 B 细胞淋巴瘤（DLBCL）的更新，主要集中在 MYC 阳性 DLBCL 的出现；早期疾病中成像的有限作用；新的治疗选择；肿瘤异质性的挑战；以及起源细胞在未来治疗选择中的影响。然后，Zelenetz 博士代表 Steven Horwitz 博士介绍了原发性皮肤 CD30+ T 细胞淋巴增生性疾病和 T 细胞大颗粒淋巴细胞白血病的新指南。
Zotero 插件